Skip to main navigation Skip to search Skip to main content

Early Anti-Drug Antibodies Predict Adalimumab Response in Juvenile Idiopathic Arthritis

  • Bo Han Huang
  • , Jr Lin Hsu
  • , Hsin Yi Huang
  • , Jing Long Huang
  • , Kuo Wei Yeh
  • , Li Chen Chen
  • , Wen I. Lee
  • , Tsung Chieh Yao
  • , Liang Shiou Ou
  • , Syh Jae Lin
  • , Kuan Wen Su
  • , Chao Yi Wu*
  • *Corresponding author for this work
  • Chang Gung Memorial Hospital
  • Chang Gung University
  • National Yang Ming Chiao Tung University
  • New Taipei Municipal Tucheng Hospital
  • Chang Gung University of Science and Technology

Research output: Contribution to journal › Journal Article › peer-review

7 Scopus citations

Abstract

Adalimumab, a TNF-alpha inhibitor, is approved to treat juvenile idiopathic arthritis (JIA), helping control disease activity and reduce flare frequency. This study aims to investigate predictors of treatment response, including anti-drug antibodies. We reviewed 65 JIA patients (mean age 10.47 ± 3.90 years; 61.5% male) receiving adalimumab for an average of 2.64 ± 0.56 years, with demographics, laboratory parameters, therapeutic regimens, and treatment outcomes recorded. Disease status was evaluated using the Wallace criteria up to 36 months post-treatment initiation, and anti-adalimumab antibody levels were measured after 6 months of treatment. Enthesitis-related arthritis was the most common subtype (64.6%). Inactive disease status was achieved by 83.1% of patients, with 59.3% experiencing relapse. Detectable anti-adalimumab antibody at six months (p = 0.023) and temporomandibular joint (TMJ) involvement (p = 0.038) identified those less likely to achieve inactive disease. An antibody level cutoff of 7.426 ng/mL best predicted response (AUC = 0.808; p = 0.008), while high anti-adalimumab antibody levels after treatment (p = 0.032) and an injection intervals over two weeks (p = 0.042) were predictors of future flares. Our results highlight that the presence of anti-adalimumab antibodies six months after treatment is a risk factor for poor response to adalimumab therapy.

Original languageEnglish
Article number1189
JournalInternational Journal of Molecular Sciences
Volume26
Issue number3
DOIs
StatePublished - 30 01 2025

Bibliographical note

Publisher Copyright:
© 2025 by the authors.

Keywords

  • adalimumab
  • anti-drug antibodies
  • enthesitis-related arthritis
  • immunogenicity
  • juvenile idiopathic arthritis
  • outcome
  • risk factors

Fingerprint

Dive into the research topics of 'Early Anti-Drug Antibodies Predict Adalimumab Response in Juvenile Idiopathic Arthritis'. Together they form a unique fingerprint.

Cite this